Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Company Overview More
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
CEO: Leonard M.D., John M.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist

NTLA Intellia Therapeutics

Watchlist
47.740+0.030+0.06%
Close 05/20 20:00 ET
47.500-0.24-0.50%
Post Mkt Price 05/20 19:52 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
50.200
Open
48.760
Turnover
52.83M
Low
43.490
Pre Close
47.710
Volume
1.14M
Market Cap
3.62B
P/E(TTM)
Loss
52wk High
202.730
Shares
75.85M
P/E(Static)
Loss
52wk Low
38.850
Float Cap
3.28B
Bid/Ask %
-84.61%
Historical High
202.730
Shs Float
68.68M
Volume Ratio
1.12
Historical Low
9.180
Dividend TTM
--
Div Yield TTM
350
P/B
3.80
Dividend LFY
--
Div Yield LFY
733.14%
Turnover Ratio
1.66%
Amplitude
14.06%
Avg Price
46.253
Lot Size
1
Float Cap
3.28B
Bid/Ask %
-84.61%
Historical High
202.730
Shs Float
68.68M
Volume Ratio
1.12
Historical Low
9.180
Dividend TTM
--
P/B
3.80
Dividend LFY
--
Turnover Ratio
1.66%
Amplitude
14.06%
Avg Price
46.253
Lot Size
1
Price Forecast

No Data

News

Comment

Back to the Top